Time to get in?_老虎社区_美港股上老虎

Jeffdad
2021-08-12

Time to get in?

Why Moderna Stock Crashed Today

What happened Shares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulat

Why Moderna Stock Crashed Today

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":895677704,"tweetId":"895677704","gmtCreate":1628743672708,"gmtModify":1631885101612,"author":{"id":3582785880297802,"idStr":"3582785880297802","authorId":3582785880297802,"authorIdStr":"3582785880297802","name":"Jeffdad","avatar":"https://static.tigerbbs.com/55fc04cec1892dd2d910600d9087116b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Time to get in?</p></body></html>","htmlText":"<html><head></head><body><p>Time to get in?</p></body></html>","text":"Time to get in?","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/895677704","repostId":1153877356,"repostType":4,"repost":{"id":"1153877356","kind":"news","pubTimestamp":1628738808,"share":"https://www.laohu8.com/m/news/1153877356?lang=&edition=full","pubTime":"2021-08-12 11:26","market":"hk","language":"en","title":"Why Moderna Stock Crashed Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1153877356","media":"The motley fool","summary":"What happened\nShares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulat","content":"<p>What happened</p>\n<p>Shares of&nbsp;<b>Moderna</b>(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulator provided a COVID-19 vaccine-safety update.</p>\n<p>So what</p>\n<p>The European <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> Agency (EMA) is studying three new conditions reported by a small number of people who received mRNA COVID-19 vaccines provided by Moderna and<b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b>.</p>\n<p>These conditions include:</p>\n<ul>\n <li>Erythema multiforme, an allergic skin reaction.</li>\n <li>Glomerulonephritis, or kidney inflammation.</li>\n <li>Nephrotic syndrome, a renal disorder.</li>\n</ul>\n<p>The EMA is assessing whether these conditions could be possible side effects of the vaccines.</p>\n<p>The information was provided as part of ongoing safety updates the EMA regularly delivers to the public. The EMA did not recommend any changes to the product information displayed on the labels of these vaccines.</p>\n<p>Now what</p>\n<p>Analysts had already raised concerns that Moderna's stock price had risen too far, too fast.<b><a href=\"https://laohu8.com/S/BAC\">Bank of America</a></b>analyst Geoff Meacham said on Tuesday that Moderna's nearly $200 billion marketvaluationwas \"ridiculous\" and \"unjustifiable on a fundamental basis.\" Meacham argued that to be worth that much, Moderna would need to deliver between 1 billion and 1.5 billion doses of its coronavirus vaccine each year through 2038. Additionally, Moderna's entire pipeline of experimental drugs would need to prove successful and generate total peak sales of $30 billion.</p>\n<p>Meacham believes those two assumptions are highly unlikely, so he repeated his underperform rating on Moderna's stock and $115 price forecast for its shares. Even after today's plunge, Meacham's price target is still 70% below the stock's current price near $385.</p>\n<p>Today's news and Meacham's warning appear to have driven many investors to take profits and sell their shares in Moderna.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Stock Crashed Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Stock Crashed Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-12 11:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/11/why-moderna-stock-crashed-today/><strong>The motley fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulator provided a COVID-19 vaccine-safety update.\nSo what\nThe European Medicines Agency (EMA) is ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/11/why-moderna-stock-crashed-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/08/11/why-moderna-stock-crashed-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1153877356","content_text":"What happened\nShares of Moderna(NASDAQ: MRNA) plunged 15.6% on Wednesday after Europe's drug regulator provided a COVID-19 vaccine-safety update.\nSo what\nThe European Medicines Agency (EMA) is studying three new conditions reported by a small number of people who received mRNA COVID-19 vaccines provided by Moderna andPfizer.\nThese conditions include:\n\nErythema multiforme, an allergic skin reaction.\nGlomerulonephritis, or kidney inflammation.\nNephrotic syndrome, a renal disorder.\n\nThe EMA is assessing whether these conditions could be possible side effects of the vaccines.\nThe information was provided as part of ongoing safety updates the EMA regularly delivers to the public. The EMA did not recommend any changes to the product information displayed on the labels of these vaccines.\nNow what\nAnalysts had already raised concerns that Moderna's stock price had risen too far, too fast.Bank of Americaanalyst Geoff Meacham said on Tuesday that Moderna's nearly $200 billion marketvaluationwas \"ridiculous\" and \"unjustifiable on a fundamental basis.\" Meacham argued that to be worth that much, Moderna would need to deliver between 1 billion and 1.5 billion doses of its coronavirus vaccine each year through 2038. Additionally, Moderna's entire pipeline of experimental drugs would need to prove successful and generate total peak sales of $30 billion.\nMeacham believes those two assumptions are highly unlikely, so he repeated his underperform rating on Moderna's stock and $115 price forecast for its shares. Even after today's plunge, Meacham's price target is still 70% below the stock's current price near $385.\nToday's news and Meacham's warning appear to have driven many investors to take profits and sell their shares in Moderna.","news_type":1},"isVote":1,"tweetType":1,"viewCount":488,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["TWX","TIME"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}